nanoTox CSO to Speak on Regulations and Policies Affecting Nanotechnology Companies at NSTI Nanotech

Published on April 23, 2009 at 7:41 PM

nanoTox Inc., the first company to provide complete risk assessment - and solutions - exclusively for nanoparticles, announced today that its Chief Scientific Officer, Dr. David W. Hobson, will share his insight on impending regulations and policies surrounding nanotech product safety during the NSTI Nanotech conference and exposition in Houston, Texas. The panel, entitled "Nanotech Policy, Regulation and Product Safety," will take place at 1:30 pm on May 5, 2009 at the George R. Brown Convention Center.

Dr. Hobson is a toxicological expert on safety issues related to the commercialization of nanotechnology and is a noted consultant to government and industry on nanoproduct and nanotechnology development issues.

"The nanotechnology platform is demonstrating amazing potential for the development of advanced technologies and products in many business sectors," stated Dr. Hobson. "Recent actions in the U.S. and abroad requiring nanotechnology companies to list certain materials they incorporate into commercial products are just the start of events that will have lasting effects on nanotechnology companies and the marketplace for nanoproducts."

Dr. Hobson has 30 years of practical experience in toxicological research and development, including environmental, industrial, and medical projects for government, industry and private concerns. His experience with nanomaterials includes pharmacological and toxicological research using in vitro and in vivo pre-clinical models; preparation of medical device submissions to regulatory agencies, as well as chemistry and manufacturing controls and pharmacology/toxicology sections for new drug applications. His work with nanoTox includes establishing state-of-the-art facilities and test procedures, which are employed for clients under strict confidentiality and in accordance with established U.S. good laboratory practices and international data quality standards.

Dr. Hobson is a past president of the American College of Toxicology and an editorial advisor to the International Journal of Toxicology. He teaches courses in biophysics, nuclear pharmacy, immunoassay and radiation biology at the University of the Incarnate Word in San Antonio.

Dr. Hobson has many scientific publications to his credit including the book Dermal and Ocular Toxicology: Fundamentals and Methods; and book chapters on product risk assessment, toxicology study design, toxicology of wound healing, dermal toxicology and gastrointestinal toxicology. He has led successful projects including all aspects of pharmaceutical development - from discovery, development and registration to post-market support - which have resulted in currently marketed pharmaceutical products and numerous patents.

nanoTox will be exhibiting at the NSTI Nanotech conference and exposition May 3-7, 2009. The nanoTox booth, #907, will be located near the front of the exhibit hall.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit